NASDAQ:PBYI Puma Biotechnology (PBYI) Stock Price, News & Analysis $3.29 +0.04 (+1.23%) Closing price 04:00 PM EasternExtended Trading$3.13 -0.16 (-4.86%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Puma Biotechnology Stock (NASDAQ:PBYI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Puma Biotechnology alerts:Sign Up Key Stats Today's Range$3.22▼$3.3250-Day Range$3.07▼$3.7252-Week Range$2.22▼$4.06Volume501,035 shsAverage Volume305,247 shsMarket Capitalization$163.28 millionP/E Ratio4.27Dividend YieldN/APrice Target$7.00Consensus RatingBuy Company Overview Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California. Read More Puma Biotechnology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks77th Percentile Overall ScorePBYI MarketRank™: Puma Biotechnology scored higher than 77% of companies evaluated by MarketBeat, and ranked 219th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingPuma Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoveragePuma Biotechnology has received no research coverage in the past 90 days.Read more about Puma Biotechnology's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth22.58% Earnings GrowthEarnings for Puma Biotechnology are expected to grow by 22.58% in the coming year, from $0.31 to $0.38 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Puma Biotechnology is 4.27, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.64.Price to Earnings Ratio vs. SectorThe P/E ratio of Puma Biotechnology is 4.27, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.57.Price to Book Value per Share RatioPuma Biotechnology has a P/B Ratio of 1.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Puma Biotechnology's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.99% of the float of Puma Biotechnology has been sold short.Short Interest Ratio / Days to CoverPuma Biotechnology has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Puma Biotechnology has recently decreased by 0.76%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPuma Biotechnology does not currently pay a dividend.Dividend GrowthPuma Biotechnology does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.99% of the float of Puma Biotechnology has been sold short.Short Interest Ratio / Days to CoverPuma Biotechnology has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Puma Biotechnology has recently decreased by 0.76%, indicating that investor sentiment is improving. News and Social Media0.9 / 5News Sentiment-0.32 News SentimentPuma Biotechnology has a news sentiment score of -0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Puma Biotechnology this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 1 people have added Puma Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Puma Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $596,914.00 in company stock.Percentage Held by Insiders23.30% of the stock of Puma Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.29% of the stock of Puma Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Puma Biotechnology's insider trading history. Receive PBYI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Puma Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address PBYI Stock News HeadlinesPuma Biotechnology, Inc. (NASDAQ:PBYI) Director Sells $90,990.00 in StockJuly 23, 2025 | insidertrades.comPuma Biotechnology, Inc. (NASDAQ:PBYI) Insider Sells $12,188.22 in StockJuly 11, 2025 | insidertrades.com$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.August 7 at 2:00 AM | Brownstone Research (Ad)Puma Biotechnology, Inc. (PBYI) Q2 2025 Earnings Call Transcript4 hours ago | seekingalpha.comPuma Biotechnology (NASDAQ:PBYI) shareholders have endured a 70% loss from investing in the stock five years agoAugust 2, 2025 | finance.yahoo.comPuma Biotechnology to Host Conference Call to Discuss Second Quarter 2025 Financial ResultsJuly 24, 2025 | businesswire.comWhy Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for ... - NasdaqJuly 12, 2025 | nasdaq.comPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)July 2, 2025 | businesswire.comSee More Headlines PBYI Stock Analysis - Frequently Asked Questions How have PBYI shares performed this year? Puma Biotechnology's stock was trading at $3.05 at the beginning of the year. Since then, PBYI stock has increased by 7.9% and is now trading at $3.29. How were Puma Biotechnology's earnings last quarter? Puma Biotechnology, Inc. (NASDAQ:PBYI) posted its earnings results on Thursday, August, 7th. The biopharmaceutical company reported $0.12 EPS for the quarter, topping the consensus estimate of $0.11 by $0.01. Puma Biotechnology had a trailing twelve-month return on equity of 49.35% and a net margin of 16.37%. Read the conference call transcript. Who are Puma Biotechnology's major shareholders? Puma Biotechnology's top institutional investors include Connor Clark & Lunn Investment Management Ltd. (1.81%), Los Angeles Capital Management LLC (0.90%), Ritholtz Wealth Management (0.40%) and Prospera Financial Services Inc (0.39%). Insiders that own company stock include Alan H Auerbach, Douglas M Hunt, Maximo F Nougues, Jeffrey Jerome Ludwig, Alvin F Wong, Jay M Moyes, Michael Patrick Miller, Alessandra Cesano and Adrian Senderowicz. View institutional ownership trends. How do I buy shares of Puma Biotechnology? Shares of PBYI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Puma Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Puma Biotechnology investors own include Incyte (INCY), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), Humana (HUM), American Water Works (AWK) and NVIDIA (NVDA). Company Calendar Last Earnings2/27/2025Today8/07/2025Next Earnings (Estimated)8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PBYI CIK1401667 Webwww.pumabiotechnology.com Phone(424) 248-6500Fax424-248-6501Employees200Year FoundedN/APrice Target and Rating Average Price Target for Puma Biotechnology$7.00 High Price Target$7.00 Low Price Target$7.00 Potential Upside/Downside+113.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)$0.77 Trailing P/E Ratio4.26 Forward P/E Ratio10.59 P/E GrowthN/ANet Income$30.28 million Net Margins16.37% Pretax Margin13.73% Return on Equity49.35% Return on Assets18.25% Debt Debt-to-Equity Ratio0.11 Current Ratio1.53 Quick Ratio1.43 Sales & Book Value Annual Sales$230.50 million Price / Sales0.71 Cash Flow$0.87 per share Price / Cash Flow3.78 Book Value$1.88 per share Price / Book1.75Miscellaneous Outstanding Shares49,630,000Free Float38,067,000Market Cap$162.89 million OptionableOptionable Beta1.30 Social Links Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:PBYI) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Puma Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Puma Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.